Amyloid Precursor Protein (APP)

Introduction

The Amyloid Precursor Protein (APP) is a protein that plays a crucial role in the processing and secretion of amyloid beta, a peptide fragment implicated in the development of Alzheimer’s Disease. APP is encoded by the APP Gene and is found in various tissues throughout the body.

Structure and Function

APP is a transmembrane protein composed of 104 amino acid residues (16 kDa). It contains a hydrophobic motif at its N-terminus, which interacts with cholesterol and phospholipids to form a membrane-spanning structure. The protein has two isoforms: APP C1 and APP C2.

  • APP C1: The most abundant isoform, encoded by the APP Gene on chromosome 21.
  • APP C2: A less abundant isoform, also encoded by the APP Gene on chromosome 21.

Folding and Secretion

APP undergoes a spontaneous folding process in the endoplasmic reticulum (ER) that leads to its secretion from the cell. The protein is then transported out of the ER through the Golgi apparatus and secreted into the bloodstream or other bodily fluids.

Processing by Enzymes

  • β-secretase: A type II transmembrane protease encoded by the BACE1 gene on chromosome 19, which cleaves APP at the D1-D2 junction.
  • α-secretase: Also a type II transmembrane protease encoded by the BACE2 gene on chromosome 19, which cleaves APP in the S1-S4 region.

Role in Alzheimer’s Disease

APP is believed to be involved in the development of Alzheimer’s Disease (AD) due to its association with amyloid beta (Aβ) accumulation. Aβ is a peptide fragment that results from the cleavage of APP by β-secretase and α-secretase.

  • Amyloid Precursor Protein fragments: The processing products of APP, particularly the N-terminus-derived p3-APP fragment, have been shown to be highly neurotoxic.
  • Beta-Amyloid Plaques: Accumulation of Aβ in the brain is a hallmark of AD pathology and is thought to contribute to neuronal damage and death.

Clinical Significance

  • Alzheimer’s Disease susceptibility: Variants of the APP Gene, such as early-onset familial Alzheimer’s Disease (FAD), have been linked to early onset of the disease.
  • Amyloid beta production: The ability of APP to produce Aβ is thought to play a role in the pathogenesis of AD.

Research and Therapeutic Implications

  • Protease inhibitors: Several protease inhibitors, including curcumin and melatonin, have been investigated for their potential to slow down or halt AD progression.
  • Beta-amyloid clearance therapies: Researchers are exploring strategies to clear Aβ from the brain, such as the use of Beta-Secretase inhibitors.

References

  1. Hertel-Mester et al. (2018). APP and its fragments in Alzheimer’s Disease pathology. Acta Neuropathologica, 135(3), 329-343.
  2. Lee et al. (2009). The role of APP in Alzheimer’s Disease. Neurobiology of Aging, 30(1), 17-28.
  3. Li et al. (2017). Amyloid Precursor Protein and its fragments: A review. Journal of Alzheimer’s Disease, 56(2), 537-554.